35/395 184/1,753 Tau 2 = 0.00, I 2 = 0.0%, p = 0.065 Prophylaxis 26% 0.74 [0.54-1.02] 35/1,012 184/10,342 26% lower risk All studies 30% 0.70 [0.52-0.95] 37/1,035 198/10,372 30% lower risk 4 vitamin B12 COVID-19 studies c19 early .org July 2026 Tau 2 = 0.00, I 2 = 0.0%, p = 0.023 Effect extraction pre-specified (most serious outcome, see appendix) Favors vitamin B12 Favors control Download Image 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bejan 34% 0.66 [0.30-1.44] 617 (n) 8,589 (n) Improvement, RR [CI] Treatment Control Tau 2 = 0.00, I 2 = 0.0%, p = 0.3 Prophylaxis 34% 0.66 [0.30-1.44] 617 (n) 8,589 (n) 34% lower risk All studies 34% 0.66 [0.30-1.44] 617 (n) 8,589 (n) 34% lower risk 1 vitamin B12 COVID-19 mortality result c19 early .org July 2026 Tau 2 = 0.00, I 2 = 0.0%, p = 0.3 Favors vitamin B12 Favors control Download Image 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Erfani (RCT) -1% 1.01 [0.72-1.41] hosp
Munib took a careful, evidence-based approach
Step Four: Calculate the Market-based Relative Weights: For each MS-DRG, the market-based relative weight would be calculated as the ratio of the single weighted average standardized median MAO payer-specific negotiated charge for that MS-DRG across hospitals from Step Two to the single national weighted average standardized median MAO payer-specific negotiated charge across all MS-DRGs from Step Three
In the short term, insufficient B-12 levels can trigger deep fatigue, mood fluctuations, and cognitive changes resembling dementia, hindering your vitality and optimal performance
